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https://doi.org/10.1016/j.stemcr.2019.06.007SUMMARYFor long QT syndrome (LQTS), recent progress in genome-sequencing technologies enabled the identification of rare genomic variants
with diagnostic, prognostic, and therapeutic implications. However, pathogenic stratification of the identified variants remains chal-
lenging, especially in variants of uncertain significance. This study aimed to propose a phenotypic cell-based diagnostic assay for iden-
tifying LQTS to recognize pathogenic variants in a high-throughput manner suitable for screening. We investigated the response of
LQT2-induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iPSC-CMs) following IKr blockade using a multi-electrode array,
finding that the response to IKr blockade was significantly smaller than in Control-iPSC-CMs. Furthermore, we found that LQT1-iPSC-
CMs and LQT3-iPSC-CMs could be distinguished from Control-iPSC-CMs by IKs blockade and INa blockade, respectively. This strategy
might be helpful in compensating for the shortcomings of genetic testing of LQTS patients.INTRODUCTION
Long QT syndrome (LQTS) is caused by hereditary cardiac
channelopathies characterized by a prolonged QT interval
and abnormal T-wave morphology on electrocardiograms
and capable of precipitating malignant arrhythmia (i.e.,
Torsade de Pointes [TdP]), resulting in syncope and sudden
death (Moss, 2003). Genetic tests are currently utilized to
assist treatment selection and prognostication (Napolitano
et al., 2005); however, the advent of high-output
sequencing techniques using next-generation sequencing
has allowed identification of an extremely large number
of variants from both patients and healthy individuals.
Given the extreme clinical importance of identifying path-
ogenic variants among those of uncertain significance (i.e.,
VUSs) (Horie, 2016), a phenotype-based high-throughput
diagnostic test is required to identify clinically relevant ge-
netic abnormalities.
Giudicessi and Ackerman (2013) suggested ‘‘current-
centric’’ classification of LQTS-susceptibility genes, which
is reasonable in termsofphenotype-baseddiagnosis and sub-
sequent treatment selection.However, current-centric classi-
fication is difficult in clinical settings. Although the use of
provocative tests, including exercise-stress tests and drug-
infusion tests, has been proposed to predict the LQTS geno-
types, it remains difficult to appropriately diagnose and
manage decisions based on their results (Priori et al., 2013).
Human induced pluripotent stem cell (iPSC) technology
is promising for cell transplantation and disease modeling394 Stem Cell Reports j Vol. 13 j 394–404 j August 13, 2019 j ª 2019 The A
This is an open access article under the CC BY license (http://creativecommofor diagnosis, investigation of disease mechanisms, and
identification of new drugs (Hamazaki et al., 2017; Inoue
and Yamanaka, 2011; Takahashi et al., 2007). Because iPSCs
retain the genetic information of the cells fromwhich they
are derived, cells differentiated from iPSCs can potentially
recapitulate the phenotypic variation of each donor. There-
fore, iPSC-derived cardiomyocytes (iPSC-CMs) potentially
play a key role in various fields of regenerative medicine
(Egashira et al., 2011) andmight represent a powerful diag-
nostic tool for LQTS.
Here, we demonstrated that iPSC-CMs can be applied to
phenotypic, cell-based, high-throughput screening for
recognition and classification of LQTS by using iPSCs
from patients with LQTS types 1, 2, and 3, which account
for 90% of all LQTS.
RESULTS
Clinical Phenotype of LQTS Patients Enrolled in this
Study and Genetic Mutations
All patients enrolled in this study were symptomatic, except
for an LQT2 patient harboring potassium voltage-gated
channel subfamily Hmember 2 (KCNH2) p.G601S (Table 1).
All mutations were located in the transmembrane or
pore domains, thereby causing heterozygous missense mu-
tations in KCNH2 and sodium voltage-gated channel alpha
subunit 5 (SCN5A) and splicing errors in potassium
voltage-gated channel subfamily Qmember 1 (KCNQ1) (Fig-
ure 1A). The sequence of gene-corrected LQT2A422T-iPSCsuthor(s).
ns.org/licenses/by/4.0/).
Table 1. Information on Patients Enrolled in the Present Study
LQTS
Type Mutation
Age
(years) Sex
Corrected QT
Interval Symptom
LQT1 KCNQ1 11 Male 424 ms Cardiac arrest
A344Aspl 500 ms on
exercise
Ventricular
fibrillation
LQT2 KCNH2 53 Female 493 ms Syncope
A422T
KCNH2 14 Female 480 ms Asymptomatic
G601S
LQT3 SCN5A 20 Female 522 ms Sudden death
N406K
Healthy Control 46 Male 443 ms None
36 Female No QT
prolongation
None(LQT2A422T-corr-iPSCs) and LQT3N406K-iPSCs (LQT3corr-
iPSCs) was confirmed by Sanger sequencing (Figure 1B).
LQT2A422T- and LQT2G601S-iPSC-CMs Display Smaller
Responses to IKr Blockade
We hypothesized that IKr contribution to repolarization
could be indirectly evaluated by assessing the field-
potential (FP) response to IKr blockade. At baseline,
the corrected LQT2A422T-iPSC-CM FP duration (FPDc)
was significantly longer than that in Control-
and LQT2 A422T-corr-iPSC-CMs (301.0 ± 15.7 ms,
202.2 ± 10.8 ms, and 180.2 ± 20.9 ms, respectively; p <
0.05) (Figures 2A and 2B). To verify our hypothesis, we
blocked IKr using E4031 in LQT2
G601S- and LQT1A344Aspl-
iPSC-CMs. Figure 2C displays representative FP traces in
each CM group treated with 30, 100, and 300 nmol/L
E4031. To evaluate the contribution of blocked IKr to
CM repolarization, we calculated %DFPDc of iPSC-CMs
except for those with early afterdepolarizations (EADs).
Upon administration of 100 and 300 nmol/L E4031, the
%DFPDc of LQT2A422T- and LQT2G601S-iPSC-CMs was
significantly smaller than that of Control-, LQT2A422T-
corr-, and LQT1A344Aspl-iPSC-CMs (Figure 2D). These
results suggested that %DFPDc upon IKr blockade reflected
the density of IKr. Regarding the FPDc value, LQT1
A344Aspl-
iPSC-CMs showed the most prolonged FPDc among the
five iPSC-CM lines (Figure S1A).
During the prolonged FPD by IKr blockade, EADs were re-
corded in each cell line (Figure 2E), revealing that, upon
less than 100 nmol/L E4031, the occurrence rate of EADs
was significantly higher in LQT2A422T-iPSC-CMs than in
Control-, LQT2A4222T-corr-, LQT2G601S-, or LQT1A344Aspl-
iPSC-CMs (Figure 2F). These data suggested thatLQT2A422T-iPSC-CMs were more vulnerable to arrhythmic
events.
Patch-Clamp Results Show Reduced IKr and
Attenuated Response to IKr Blockade in LQT2
A422T-
iPSC-CMs
To investigate the IKr in differentiated CMs, we
performed patch-clamp electrophysiological analysis,
with IKr current detected as an E4031-sensitive current
(Figure 3A). IKr tail current densities in LQT2
A422T-corr-
iPSC-CMs increased significantly as compared with those
in LQT2A422T-iPSC-CMs according to the whole-cell
patch-clamp method (peak IKr density: LQT2
A422T, 1.01 ±
0.11 pA/pF; LQT2 A422T-corr, 1.85 ± 0.16 pA/pF) (Figure 3B),
indicating that gene correction normalized the reduced IKr
observed in LQT2A422T-iPSC-CMs. We then evaluated ac-
tion potential duration (APD) to assess the contribution
of IKr to repolarization (Figure 3C), finding that the APD90
in Control-, LQT2A422T-, and LQT2 A422T-corr-iPSC-CMs
was 215.8 ± 16.2 ms, 321.1 ± 37.0 ms, and 216.4 ±
24.4 ms, respectively (p < 0.05), whereas the AP amplitude
and maximum diastolic potential (MDP) did not differ
significantly (Figure 3D).
To confirm IKr blockade-mediated FPD prolongation, we
evaluated APD prolongation upon IKr blockade. Because
MDP elevation due to IKr blockage disturbed correct APD
measurement in some samples (Figure S2A), MDPwas fixed
at approximately –80 mV by introducing an artificial IK1
current using the dynamic clamp method (Table 2;
Figure S2B), thereby allowing the evaluation of APD pro-
longation in the presence of IKr blockade (Figures 3E
and S2A). APD90 prolongation induced by treatment
with a higher concentration of E4031 was significantly
shorter in LQT2A422T-iPSC-CMs than in Control- and
LQT2 A422T-corr-iPSC-CMs (28.4 ± 4.4% versus 85.8 ±
10.7% and 82.1 ± 10.7%, respectively; p < 0.05), with the
APD50 showing a similar pattern of prolongation (10.4 ±
2.6% versus 48.6 ± 10.2% and 53.4 ± 12.5%, respectively;
p < 0.05). These responses to E4031 were compatible with
those observed in FPD experiments (Figure 3F). These
data rigorously supported the multi-electrode array (MEA)
results, showing that the response to IKr blockade reflected
IKr density.
LQT1A344Aspl-iPSC-CMs Display an Attenuated
Response to IKs Blockade
We then performed IKs blockade to elucidate IKs deficiency
by using different concentrations of chromanol 293B. At
baseline, the FPDc of LQT1A344Aspl-iPSC-CMs was longer
than that of Control-iPSC-CMs (249.4 ± 14.0 ms and
202.2 ± 10.8 ms, respectively; p < 0.05) (Figures 4A and
4B). Figure 4C shows representative FP traces in each CM
group treated with 10, 50, and 100 mmol/L chromanolStem Cell Reports j Vol. 13 j 394–404 j August 13, 2019 395
Figure 1. Introduction of iPSC Lines Used
in This Study
(A) Summary of topologies of mutations of
iPSC lines used in this study. LQT1A344Aspl
carries a heterozygous KCNQ1 mutation
(c.1032C > A, p.A344Aspl); LQT2A422T
and LQT2A422T-corr are the isogenic pair
harboring the heterozygous KCNH2 mutation
(c.1264G > A, p.A422T) and the corrected
sequence, respectively; LQT2G601S carries a
heterozygous KCNH2 mutation (c.1801G > A,
p.G601S); and LQT3N406K and LQT3corr are the
isogenic pair harboring the heterozygous
SCN5A mutation (c.1218C > A, p.N406K) and
the corrected sequence, respectively.
(B) Sequence analysis of PCR-amplified
genomic DNA of the isogenic pair of LQT2A422T
and LQT2 A422T-corr and of LQT3N406K and
LQT3corr, respectively. The gene-corrected cell
lines harbor several silent mutations (white
arrow head) to avoid further digestion by
CRISPR/Cas9.293B. Upon administration of 100 mmol/L chromanol
293B, LQT1A344Aspl-iPSC-CMs showed a significantly
smaller %DFPDc than those observed in Control-,
LQT2A422T-, and LQT3N406K-iPSC-CMs (Figure 4D). These
results suggested that the effect of IKs blockade on FPD pro-
longation reflected the IKs density. Regarding the FPDc
value, LQT2A422T-iPSC-CMs exhibited the longest FPDc
among the three lines at 100 mmol/L chromanol 293B
(Figure S1B).
LQT3N406K-iPSC-CMsDisplay aGreater Response to INa
Blockade, which Was Normalized by Gene Correction
We then blocked INa using tetrodotoxin (TTX) in order to
elucidate the excessive INa-Late response. At baseline, the
FPDc of LQT3N406K-iPSC-CMs was longer than that of the
correctedLQT3-iPSC-CMs(LQT3corr-iPSC-CMs) (Figure5A).396 Stem Cell Reports j Vol. 13 j 394–404 j August 13, 2019Figure 5B shows representative FP traces in each CM
group treated with 400 nmol/L TTX. Upon administration
of 400 nmol/L of TTX, the %DFPDc for Control-,
LQT3N406K-, LQT3corr-, LQT1A344Aspl-, and LQT2A422T-
iPSC-CMs was –6.8 ± 2.8%, –19.0 ± 2.6%, –4.8 ± 2.0%,
–3.0 ± 3.8%, and –6.6 ± 3.6% (p < 0.05), respectively. A
similar response was observed using mexiletine, another
typical INa blocker (Figure 5C).
%DFPDc on Specific Current Blockade Is a Better
Predictor for Estimating LQTS Subtype than Baseline
FPDc in the iPSC-CM Model
To determine the accuracy of specific current blockade,
receiver operating characteristic (ROC) curve analysis
was performed in each cell line. Although the area under
the ROC curves (AUCs) for baseline FPDc were <0.75, the
Figure 2. Functional Analysis of iPSC-CMs
Using MEA Following IKr Blockade
(A) Representative traces of FP in Control-,
LQT2A422T-, LQT2A422T-corr-, and LQT2G601S-
iPSC-CMs.
(B) FPDc baseline data in Control-,
LQT2A422T-, LQT2corr-, and LQT2G601S-iPSC-
CMs (independent experiments, n = 45, 35,
12, and 9 from independent differentiation
experiments, n = 16, 11, 6, and 3, respec-
tively; mean ± SEM; p = 0.001; one-way
ANOVA). *p < 0.05, Fisher’s LSD post hoc test.
(C) Representative traces of the FPD
following administration of 30 nmol/L (red),
100 nmol/L (green), and 300 nmol/L (blue)
E4031.
(D) Averaged FPDc ratio before and after
E4031 treatment (%DFPDc) in Control-,
LQT2A422T-, LQT2A422T-corr-, LQT2G601S-, and
LQT1A344Aspl-iPSC-CMs. FPDc prolongation
upon treatment with 100 and 300 nmol/L
E4031 was smaller in LQT2A422T- and
LQT2G601S-iPSC-CMs than in Control-,
LQT2corr-, or LQT1A344Aspl-iPSC-CMs (inde-
pendent experiments, n = 23, 24, 12, 9, and
12 from independent differentiation experi-
ments, n = 8, 8, 6, 3, and 3 in Control-,
LQT2A422T-, LQT2A422T-corr-, LQT2G601S-, and
LQT1A344Aspl-iPSC-CMs, respectively; mean ±
SEM; p = 0.025; two-way repeated measures
ANOVA). *p < 0.05, Fisher’s LSD post hoc test.
(E) Examples of EADs. EAD documented in a
sample of LQT2A422T-iPSC-CMs before E4031
treatment (upper) and following 30 nmol/L
E4031 treatment (lower).
(F) Percentage of samples in which
EADs occurred in Control-, LQT2A422T-,
LQT2A422T-corr-, and LQT2G601S-iPSC-CMs. The
number on top of each bar shows the number
of arrhythmic events. *p < 0.05; Pearson’s
Chi-square test.
See also Figure S1.AUCs for %DFPDc following specific current blockade
were significantly improved, indicating that specific cur-
rent blockade enhanced the detectability of the abnormal
current (Figure 5D; Table S1).DISCUSSION
Among >15 different LQTS subtypes based on responsible
pathogenic genes (Schwartz et al., 2013), LQT1, LQT2,
and LQT3 are the most common. In LQT1, exercise or
emotional stress often triggers arrhythmias, with b blockers
the most effective at preventing these arrhythmic events(Moss et al., 2000; Priori et al., 2004; Schwartz et al.,
2001). By contrast, in LQT2, drugs or hypopotassemia
trigger TdP, and b blockers are less effective than in LQT1.
In LQT3, TdP is triggered during sleep, and mexiletine rep-
resents a therapeutic option based on its suppression of
excessive INa-Late. Therefore, precise classification of LQTS
subtypes is clinically important for determining therapeu-
tic strategies and predicting prognosis (Inoue and Yama-
naka, 2011). In clinical settings, genetic testing is often per-
formed to assist clinical diagnosis of LQTS; however, it
identifies variants in LQTS-related genes in only 60% of
cases (Kapa et al., 2009; Wehrens et al., 2002). In addition,
not all identified variants are proven to be causative, withStem Cell Reports j Vol. 13 j 394–404 j August 13, 2019 397
Figure 3. Electrophysiological Properties
of iPSC-CMs and AP Response to IKr
Blockade
(A) Representative current traces of the IKr in
Control-, LQT2A422T-, and LQT2A422T-corr-iPSC-
CMs.
(B) Average current-voltage relationships for
peak tail currents in Control-, LQT2A422T-, and
LQT2A422T-corr-iPSC-CMs (independent experi-
ments, n = 8, 6, and 5 from independent dif-
ferentiation experiments, n = 4, 4, and 3,
respectively; mean ± SEM; p = 0.029; two-way
repeatedmeasures ANOVA). *p < 0.05, Fisher’s
LSD post hoc test for Control versus LQT2A422T;
yp < 0.05, LQT2A422T-corr versus LQT2A422T.
(C) Representative traces of AP with 1-Hz
pacing.
(D) APD50 and APD90 in Control-, LQT2
A422T-,
and LQT2A422T-corr-iPSC-CMs (independent
experiments, n = 6, 9, and 11, from inde-
pendent differentiation experiments, n = 5,
6, and 5, respectively; mean ± SEM; p = 0.010
and p = 0.025 for APD50 and APD90, respec-
tively; one-way ANOVA). *p < 0.05, Fisher’s
LSD post hoc test for APD50 and APD90.
(E) Representative AP traces changed by IKr
blockade.
(F) Percentage of APD prolongation after
E4031 treatment (%DAPD) at 1-Hz pacing
in each cell line. %DAPD50 and %DAPD90
in Control-iPSC-CMs and LQT2A422T-corr-iPSC-
CMs versus LQT2A422T-iPSC-CMs (independent
experiments, n = 7, 10, and 10 from inde-
pendent differentiation experiments, n = 5,
5, and 6 in Control-, LQT2A422T-,
and LQT2A422T-corr-iPSC-CMs, respectively;
mean ± SEM; p = 0.001; two-way repeated
measures ANOVA). *p < 0.05, Fisher’s LSD
post hoc test.
See also Figure S2.
APA, action potential amplitude; MDP,
maximum diastolic potential.many having unknown pathogenicity in the absence of
information regarding their electrophysiological conse-
quences (VUSs). Moreover, abnormalities caused by vari-
ants in intronic or promoter regions might be overlooked
by genetic testing alone. Therefore, a patient-oriented diag-
nostic system based on its specific phenotype plays an
important role in compensating for the shortcomings of
genetic testing.
In this study, we successfully distinguished LQT1, LQT2,
and LQT3 based on the phenotype displayed by iPSC-CMs
to specific current blockade. In addition, we demonstrated
that this could be performed usingMEA for increased acces-398 Stem Cell Reports j Vol. 13 j 394–404 j August 13, 2019sibility to the method, as well as its enabling higher
throughput, which is optimal for screening systems. To
verify the accuracy of this protocol, we generated an ROC
curve showing significantly improved %DFPDcs upon spe-
cific current blockade as compared with FPDcs acquired at
baseline, thereby supporting the ability of the method to
recognize disease-specific iPSC-CMs. For LQT2, we per-
formed voltage-clamp and current-clamp assays to support
the MEA data, and confirmed that gene correction recov-
ered IKr density, which correlated with the normalized IKr
blockade response of the FPDc in LQT2corr-iPSC-CMs.
Consistent with these results, Holzem et al. (2016)
Table 2. Parameters of Action Potentials under IK1 Injection with Dynamic Clamp in Each Cell Line
Baseline 100 nmol/L E4031 Administration
Control LQT2A422T LQT2corr p Value Control LQT2A422T LQT2corr p Value
No. of cells 8 14 13 7 10 10
APD50 (ms) 192.8 ± 12.4
a 261.3 ± 21.6 197.7 ± 17.4a 0.026 278.7 ± 22.8b 277.9 ± 29.5 301.9 ± 51.7 0.883
APD90 (ms) 236.0 ± 14.0
a 310.2 ± 22.1 237.8 ± 19.4a 0.019 423.7 ± 25.1b 384.8 ± 37.5 412.4 ± 58.4b 0.833
MDP (mV) 81.4 ± 1.0 82.2 ± 0.4 81.1 ± 0.7 0.408 78.5 ± 1.6 81.6 ± 0.6 80.3 ± 0.7 0.102
APA (mV) 119.4 ± 2.1 124.3 ± 1.7 119.0 ± 1.8 0.066 121.8 ± 3.3 121.2 ± 2.4 120.0 ± 2.2 0.886
Cm (pF) 65.9 ± 7.9 66.5 ± 9.3 64.2 ± 10.3 0.990 61.6 ± 7.6 66.5 ± 11.5 64.2 ± 13.4 0.838
Injected IK1 (pA/pF) 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 0.874 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.955
p Values were calculated using one-way ANOVA.
APA, action potential amplitude; Cm, membrane capacitance; MDP, maximum diastolic potential; pA, picoampere; pF, picofarad.
ap < 0.05; Fisher’s LSD post hoc test for Control or LQT2corr versus LQT2A422T.
bp < 0.05; parameters of the same cell line before and after administration of 100 nmol/L E4031 were statistically compared using an unpaired Student’s t
test.demonstrated that the reduced IKr blockade response re-
flected reduced IKr expression, as shown via optical imaging
of perfused left-ventricular wedge preparations in patients
with heart failure. In addition to LQT2, we also clarified
that LQT1A344Aspl-iPSC-CMs displayed an attenuated
response to IKs blockade, and that LQT3
N406K-iPSC-CMs
displayed a greater response to INa blockade, which was
normalized by gene correction. Of significant note, each
type of LQT-iPSC-CMs showed specific response which re-
flected the impaired ion currents as follows: LQT1A344Aspl-
iPSC-CMs showed smaller %DFPDc upon IKs blockade
while they showed normal %DFPDc upon IKr blockade. In
contrast, LQT2A422T-iPSC-CMs showed smaller %DFPDc
upon IKs blockade while they showed normal %DFPDc
upon IKr blockade. These results strongly suggested that
our system has a potential to distinguish the subtypes of
LQTS. Regarding IKs blockade, no significant difference in
%DFPDc on 10 mmol/L chromanol 293B was observed.
Given the half maximal inhibitory concentration for
KCNQ1/KCNE1 is 16.1 ± 1.8 mmol/L (Bett et al., 2006), IKs
was only partially blocked. We speculated that small
portion of IKs blockade might be masked by repolarization
reserve in iPSC-CMs.
In addition, upon IKr blockade, some of the LQT2
A422T-
iPSC-CMs showed triggered activities at baseline or
30 nmol/L E4031, whereas no arrhythmic events were re-
corded in other clones, potentially because, compared
with the other clones including LQT2G601S-iPSC-CMs,
LQT2A422T-iPSC-CMs had less repolarization reserve
composed of ion currents except IKr. Moreover, this might
indicate why, upon IKr blockade, LQT2
G601S-iPSC-CMs
were less vulnerable to EADs than LQT2A422T-iPSC-CMs.
Interestingly, these results seem to be consistent with the
clinical history of donor patients, in which, while theKCNH2 p.G601S carrier remained asymptomatic, the
KCNH2 p.A422T carrier had episodes of syncope. Further
investigation of various mutations, including both patho-
genic and non-pathogenic variants, is needed to elucidate
this relationship.
Development of iPSC technology has provided increased
opportunity for investigatingmonogenic disorders, such as
LQTS, and iPSC-CMs have proven capable of recapitulating
clinical phenotypes. However, most previous experiments
were performed using labor-intensive techniques, such as
patch-clamp methods. On the other hand, MEA, which is
also used in neuronal science, improves the throughput
of electrophysiological examination and enables CMs to
exist in a less-invasive state relative to patch clamping.
Therefore, protocols combining iPSC-CMs and the MEA
system could potentially offer a less labor-intensive and
higher-throughput method for analyzing disease-specific
human CMs and could potentially lead to applications
enabling clinical diagnosis of LQTS.
This study might offer novel insight into the utility
of iPSC-CMs for phenotype-based diagnosis of LQTS.
This method has several powerful advantages. First,
although next-generation sequencing technology provides
information about a large number of rare genetic variants,
the pathophysiological significance of such variants is
often uncertain. Therefore, the method presented in
this studymight be helpful in uncovering pathophysiolog-
ical mechanisms for individuals, especially patients
with VUSs or compound mutations, as well as genotype-
negative patients. Second, this method enables a more
comprehensive and practical diagnosis of LQTS. IKr-medi-
ated LQTS includes LQT2, as well as LQT6 (potassium
voltage-gated channel subfamily E regulatory subunit 2),
whereas IKs-mediated LQTS includes not only LQT1 butStem Cell Reports j Vol. 13 j 394–404 j August 13, 2019 399
Figure 4. Functional Analysis of iPSC-CMs
Using MEA Following IKs Blockade
(A) Representative traces of FP in Control-
and LQT1A344Aspl-iPSC-CMs.
(B) FPDc at baseline was longer in
LQT1A344Aspl-iPSC-CMs than in Control-iPSC-
CMs (independent experiments, n = 45 and 21
from independent differentiation experi-
ments, n = 16 and 6 in Control- and
LQT1A344Aspl-iPSC-CMs, respectively; mean ±
SEM; p < 0.05; unpaired Student’s t test).
*p < 0.05.
(C) Representative traces of the FPD
following administration of 10 mmol/L (red),
50 mmol/L (green), and 100 mmol/L (blue)
chromanol 293B in Control- and LQT1A344Aspl-
iPSC-CMs.
(D) Averaged %DFPDc in each cell line.
%DFPDc upon treatment with 100 mmol/L
chromanol 293B was significantly smaller in
LQT1A344Aspl-iPSC-CMs than in Control-,
LQT2A422T-, and LQT3N406K-iPSC-CMs (inde-
pendent experiments, n = 6, 13, 6, and 9 from
independent differentiation experiments,
n = 3, 5, 3, and 3 in Control-, LQT1A344Aspl-,
LQT2A422T-, and LQT3N406K-iPSC-CMs, respec-
tively; mean ± SEM; p = 0.001; two-way
repeated measures ANOVA). *p < 0.05;
Fisher’s LSD post hoc test.also LQT5 (potassium voltage-gated channel subfamily E
regulatory subunit 1) and LQT11 (A-kinase anchoring pro-
tein 9), as well as INa-mediated LQTS, including LQT3, 9
(caveolin 3), LQT10 (sodium voltage-gated channel beta
subunit 4), and LQT12 (syntrophin alpha 1). Therefore,
this current-centric classification4 provides us with the
clinical ability for selective treatment. For example, mexile-
tine should be recommended for patients with INa-medi-
ated LQTS, whereas b blockers would be predicted to be
effective in all patients with IKs-mediated LQTS. To reveal
whether this protocol is more reliable, it is necessary to
evaluate the accuracy of this protocol using other cell lines.
Nevertheless, the protocol presented here offers important
clinical implications in the diagnosis and treatment of
LQTS.
This study certainly includes some limitations. We
applied Fridericia’s formula for FPD correction. However,
it is not clear whether the correction formula was valid
for iPSC-CMs or not. We used only a small number of
iPSC lines with already known pathogenic mutations and
did not test iPSCs from LQTS patients carrying VUSs or
mutations in the non-coding regions, or patients with no
detected mutations. We should also use iPSC lines from400 Stem Cell Reports j Vol. 13 j 394–404 j August 13, 2019persons, without phenotypes, despite carrying pathogenic
mutations. In addition, the lack of isogenic controls for
LQT1A344Asppl line, the lack of blind tests, the comparisons
not performed at the same day of culture, and the variable
quality and purity of the iPSC-CMs should be noted as lim-
itations in this study. As such, this study is only a prototype
and further investigation is required.
In conclusion, this study showed that the multiple sub-
types of LQT could be potentially distinguished by specific
ion-channel blockade using the MEA system with patient-
derived iPSCs, and that this protocol might serve as a novel
method to compensate for the shortcomings of genetic
testing of LQTS patients, especially in patients who have
VUSs or no identified mutations.EXPERIMENTAL PROCEDURES
iPSC Generation, and CM Differentiation and
Purification
iPSCs were generated from LQT patients and healthy controls, as
reported previously (Spencer et al., 2014; Wuriyanghai et al.,
2018). All protocols were approved by the Committee on Human
Research at Kyoto University (Kyoto, Japan) and conformed to
Figure 5. Functional Analysis of iPSC-CMs
Using MEA Following INa Blockade
(A) Representative traces of FP in LQT3N406K-
and LQT3corr-iPSC-CMs (left). FPDc at baseline
in LQT3N406K-iPSC-CMs was significantly
shortened by gene correction (right) (inde-
pendent experiments, n = 36 and 29 from
independent differentiation experiments,
n = 8 and 8 in LQT3N406K- and LQT3corr-iPSC-
CMs, respectively; mean ± SEM; p < 0.05;
unpaired Student’s t test). *p < 0.05.
(B) Representative traces of the FP following
administration of 400 nmol/L (red) TTX in
Control-, LQT3N406K-, LQT3corr-, LQT1A344Aspl-,
and LQT2A422T-iPSC-CMs (left). The response
to treatment with 400 nmol/L TTX was
significantly larger in LQT3N406K-iPSC-CMs
than in Control-, LQT3corr-, LQT1A344Aspl-, and
LQT2A422T-iPSC-CMs (right) (independent
experiments, n = 9, 11, 17, 5, and 5 from
independent differentiation experiments,
n = 4, 5, 4, 3, and 3 in Control-, LQT3N406K-,
LQT3corr-, LQT1A344Aspl-, and LQT2A422T-iPSC-
CMs, respectively; mean ± SEM; p < 0.001;
one-way ANOVA). *p < 0.05; Fisher’s LSD post
hoc test.
(C) Averaged %DFPDc on 10 mmol/L mex-
iletine in Control-, LQT3N406K-, and LQT3corr-
iPSC-CMs (independent experiments, n = 7,
11, and 12 from independent differentiation
experiments, n = 3, 3, and 5, respectively;
mean ± SEM; p < 0.001; one-way ANOVA).
*p < 0.05; Fisher’s LSD post hoc test.
(D) Comparison of AUCs for baseline FPDc and
%DFPDc upon specific current blockade for
recognizing disease-specific iPSC-CMs. Spe-
cific current blockade enhanced the accuracy
of recognizing disease-specific iPSC-CMs.
See also Table S1.the principles of the Declaration of Helsinki. iPSCs were differenti-
ated into CMs using the previously described ‘‘GiWi’’ protocol (Fig-
ure S3A) (Lian et al., 2013). Differentiated CMs were purified in
glucose-depleted lactate medium, as described previously (To-
hyama et al., 2013), and iPSC-CMs were analyzed on days 60
through 100 (Figure S3B). Details are shown in the Supplemental
Information.
Genome Editing
The target site was set to cover the mutation site, and single-guide
RNAwas constructed. Annealed oligo was inserted into the PX459
(Addgene, Cambridge, MA, USA) plasmid digested by BpiI. The tar-
geting vector was designed to include a floxed puromycin-resis-
tant drug cassette flanked by 1.5-kb homology arms, the 30 arm
of which included the gene-correcting site. The targeting vector
was constructed by assembling PCR products of the homologyarms, drug-resistant cassette, and backbone pENTR vector with
Gibson Assembly (NEB, Ipswich, MA, USA). Thereafter, several
pointmutations were inserted to avoid further digestion of the tar-
geting site.
The procedures associated with introduction of the vectors were
performed, as reported previously (Li et al., 2016). In brief, 5 mg of
the CRISPR/Cas9 vector and the targeting vector was introduced
into 1.0 3 106 iPSCs using an NEPA 21 electroporator (NEPA
GENE, Ichikawa, Japan). Several days after electroporation, drug
selection was initiated with 0.7 mg/mL puromycin. Puromycin-
resistant cells were dispersed into single cells and dissociated
onto a dish. Several days thereafter, single colonies were picked
and screened by PCR. Drug-cassette-positive cells were then
expanded, and their floxed sites were removed by Cre excision.
Sanger sequencing was performed to confirm the sequence of
the targeted site and possible off-target sites. Primers used forStem Cell Reports j Vol. 13 j 394–404 j August 13, 2019 401
genome editing are listed in the Supplemental Information
(Tables S2 and S3).Electrophysiological Recordings
MEA Recording
CMswere dissociatedwith 1mg/mL collagenase B (Roche, Roswell,
GA, USA) and Accumax (Innova Cell Technologies, San Diego, CA,
USA). CM suspension (2 mL of 1.5 3 104 cells/mL) was placed onto
the Matrigel-coated electrode (MED-P515A; Alpha MED Scientific,
Osaka, Japan) (Asakura et al., 2015). After several hours, 1 mL
RPMI/B27 medium containing 10% fetal calf serum was added.
After 2 to 3 days, the medium was replaced with RPMI/B27 me-
dium. After 6 to 20 days, the FP of spontaneously beating CMs
was recorded. FP signals were digitally sampled at 20 kHz through
0.1-Hz high-pass and 10-kHz low-pass filters using the MED64 sys-
tem (Alpha MED Scientific). FPD was defined as the interval
between a positive or negative spike and a subsequent positive
deflection, and inter-spike interval (ISI) was defined as the interval
between adjacent spikes. These parameters were automatically
measured and analyzed using Mo¨bius QT (Alpha MED Scientific).
More than 30 beats were recorded, and the FPDs and ISIs of the
final 30 beats were averaged, as described previously (Asakura
et al., 2015), which was standardized by Fridericia’s formula
(FPDc = FPD/ISI1/3) to minimize influence of a wide range of ISIs
on FPDs (Table S4). EAD was defined as relatively slow negative
spikes during the repolarizing phase, with samples displaying
irregular beating excluded when calculating FPD and ISI. EAD-pos-
itive sampleswere defined as showingmore than 5 EADs among 30
beats. The prolongation rate of FPDc (%DFPDc) was calculated as
follows: %DFPDc (%) = [(FPDc after blockade – FPDc at baseline)/
FPDc at baseline 3 100]. For specific current blockade, we used
E4031 (Wako Pure Chemicals, Osaka, Japan), chromanol 293B
(Sigma-Aldrich, St. Louis, MO, USA), TTX (Alomone Labs, Jerusa-
lem, Israel), and mexiletine (Sigma-Aldrich, Tokyo, Japan). Drug
was gently administered by taking half of themediumout, diluting
it, and then returning it to the solution. For measurement under
stable conditions, FPD was measured 30 to 60 min after drug
administration. All the data were acquired from at least three inde-
pendent experiments.
Patch-Clamp Recording
CMs dissociated with Accutase (Thermo Fisher Scientific) were
adhered onto Matrigel-coated glass coverslips for 5 days before
recording AP in current-clamp mode using the perforated patch
technique, whereas IKr was recorded from single cells in
voltage-clamp mode using the ruptured whole-cell patch tech-
nique (Ma et al., 2011). The pipette solution comprised
(in mM): 150 KCl, 5 NaCl, 2 CaCl2, 5 EGTA, 10 HEPES, and
5 MgATP (pH 7.2, adjusted with KOH), with amphotericin B
added during AP recording (0.3 mg/mL, final concentration).
The extracellular solution comprised (in mM): 150 NaCl,
5.4 KCl, 1.8 CaCl2, 1 MgCl2, 15 glucose, 15 HEPES, and 1 Na-py-
ruvate (pH 7.4, adjusted with NaOH), with 2 mM nifedipine added
during IKr recording.
Current-clamp recordings were sampled and filtered at 10 kHz.
To evaluate AP prolongation by E4031, IK1 current was artificially
injected using the dynamic clamp technique, as reported previ-
ously (Bett et al., 2013). Detailed dynamic clamp procedures are402 Stem Cell Reports j Vol. 13 j 394–404 j August 13, 2019described in the following section. Ventricular-type CMs were
defined as those exhibiting an APD90/APD50 < 1.4. E4031 admin-
istration (100 nM) was performed in ventricular-type CMs.
Before adding nifedipine for IKmeasurement, AP was recorded to
identify ventricular-type CMs. Voltage-clamp recordings were
then sampled at 2 kHz and filtered at 1 kHz. The voltage-clamp
trace was obtained as follows: after a 40-mV holding pulse, step
pulses were applied from 40 to 10 mV in 5-mV increments for
4 s and with a 10-s cycle length. The tail current was measured at
the peak immediately after the depolarizing pulse. The measured
current was standardized based on the patched cell-membrane
capacitance. Therefore, IKr was defined as the E4031-sensitive cur-
rent upon addition of 500 nM E4031 to the extracellular solution.
Pipettes pulled from thin-walled borosilicate glass capillaries
(TW150-4; World Precision Instruments, FL, USA) with a PP-830
puller (Narishige, Tokyo, Japan) exhibited between 4.0 and
7.0 MU resistance in voltage clamp and between 3.0 and 5.0 MU
resistance in current clamp. All recordings were performed at be-
tween 35C and 37C. Data were acquired with an Axon 700B
MultiClamp, Digidata 1440A digitizer hardware, and pCLAMP
10.4 software (Molecular Devices, Sunnyvale, CA, USA), as
required. All the data were acquired from at least three indepen-
dent experiments.
Real-Time IK1 Injection Using the Dynamic Clamp Technique
As described previously (Bett et al., 2013), an analog and digital I/O
board PCIe-DAS1602/16 (Measurement Computing Corporation,
Norton, MA, USA) was used to transfer the signal of membrane
voltage to the IK1 signal using the same source code. In addition,
1 pA/pF of peak IK1 was injected to fix the MDP at approximately
–80 mV in our iPSC-CMs before and after E4031 administration.
IK1 was adjusted using a potentiometer (custom-made by Inter
Medical, Nagoya, Japan). The IK1 equation was optimized for ven-
tricular cells according to previous reports (Bett et al., 2013; Koumi
et al., 1995; Van Putten et al., 2015). The equation we used was as
follows: IK1 = 0.5 3 (Vm + 85)/(1 + e
[0.0896(Vm + 85)]).
Statistical Analysis
JMP Pro 13 (SAS, Cary, NC, USA) was used for statistical analysis.
Data are presented as the mean ± SEM. An unpaired Student’s t
test or one-way analysis of variance (ANOVA), followed by Fisher’s
least significant difference (LSD) test, was used for two- or more
than two-group comparisons. For repetitive measurements, we
performed a two-way repeated measures ANOVA, followed by
Fisher’s LSD test. Pearson’s chi-square test was used to determine
independence of categorical data. Results were considered statisti-
cally significant at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2019.06.007.
AUTHOR CONTRIBUTIONS
Conceptualization, D.Y., S.B., and T.M.; Methodology, D.Y., S.B.,
T.M., and T.H.; Investigation, D.Y., H.S., T.H., K.A., K.M., H.K.,
Y.W., and Y.Y.; Writing –– Original Draft, D.Y.; Writing – Review
& Editing, S.B., T.M., K.U., B.R.C., and M.H.; Funding Acquisition,
S.B., T.M., and M.H.; Resources, S.B., T.M., K.H., B.R.C., M.H., and
T.H.; Supervision, S.B., T.M., M.H., J.T., and T.H.
ACKNOWLEDGMENTS
We thank Akitsu Hotta (Kyoto University, Kyoto, Japan) for
providing the plasmid used to construct the targeting vector, Taka-
shi Yamamoto (Hiroshima University, Hiroshima, Japan) for tech-
nical advice on genome editing, Tadahiko Matsumoto (Kyoto
University, Kyoto, Japan) for Southern blot analysis, Takashi Ashi-
hara (Shiga University of Medical Science, Otsu, Japan), Yukiko Hi-
meno (Ritsumeikan University, Kusatsu, Japan) and Akira Amano
(Ritsumeikan University, Kusatsu, Japan) for in silico technical
advice on the dynamic clamp, Yasuhiko Tomita (Public health,
Hyogo Health Service Association, Kobe, Japan) for recruitment
of a patient, and Kyoko Yoshida (Kyoto University, Kyoto, Japan)
for maintaining the cells. DNA sequencing and immunofluores-
cence analyses were performed at the Medical Research Support
Center, Graduate School of Medicine, Kyoto University. This
work was supported by the Japan Society for the Promotion of Sci-
ence KAKENHI under grant number JP17K10141 to S.B. and
25461054 to T.M., and by grants from the Japan Agency for Med-
ical Research and Development, AMED under grant number
17930004 to M.H. and 17ek09294h0001to T.M., the SENSHIN
Medical Research Foundation and the Uehara Memorial Founda-
tion. Bruce R Conklin: A founder of Tenaya Therapeutics
(https://www.tenayatherapeutics.com/), a company focused on
finding treatments for heart failure. Holds equity in Tenaya, and
Tenaya provides research support for heart failure-related research.
Received: January 13, 2019
Revised: June 29, 2019
Accepted: June 30, 2019
Published: August 01, 2019REFERENCES
Asakura, K., Hayashi, S., Ojima, A., Taniguchi, T., Miyamoto, N.,
Nakamori, C., Nagasawa, C., Kitamura, T., Osada, T., Honda, Y.,
et al. (2015). Improvement of acquisition and analysis methods
in multi-electrode array experiments with iPS cell-derived cardio-
myocytes. J. Pharmacol. Toxicol. Methods 75, 17–26.
Bett, G.C.L.,Morales,M.J., Beahm,D.L., Duffey,M.E., and Rasmus-
son, R.L. (2006). Ancillary subunits and stimulation frequency
determine the potency of chromanol 293B block of the KCNQ1
potassium channel. J. Physiol. 576, 755–767.
Bett, G.C.L., Kaplan, A.D., Lis, A., Cimato, T.R., Tzanakakis, E.S.,
Zhou, Q., Morales, M.J., and Rasmusson, R.L. (2013). Electronic
‘‘expression’’ of the inward rectifier in cardiocytes derived from
human-induced pluripotent stem cells. Heart Rhythm 10,
1903–1910.
Egashira, T., Yuasa, S., and Fukuda, K. (2011). Induced pluripotent
stem cells in cardiovascular medicine. Stem Cells Int. 2011,
348960.
Giudicessi, J.R., and Ackerman,M.J. (2013). Genotype- and pheno-
type-guided management of congenital long QT syndrome. Curr.
Probl. Cardiol. 38, 417–455.Hamazaki, T., Rouby, N., Fredette, N.C., Santostefano, K.E., and
Terada, N. (2017). Concise review: induced pluripotent stem cell
research in the era of precision medicine. Stem Cells 35, 545–550.
Holzem, K.M., Gomez, J.F., Glukhov, A.V., Madden, E.J., Koppel,
A.C., Ewald, G.A., Trenor, B., and Efimov, I.R. (2016). Reduced
response to IKr blockade and altered hERG1a/1b stoichiometry in
human heart failure. J. Mol. Cell Cardiol. 96, 82–92.
Horie, M. (2016). Molecular genetics have opened a new era for
arrhythmia research but also Pandora׳s box? J. Arrhythm. 32,
313–314.
Inoue, H., andYamanaka, S. (2011). The use of induced pluripotent
stem cells in drug development. Clin. Pharmacol. Ther. 89,
655–661.
Kapa, S., Tester, D.J., Salisbury, B.A., Harris-Kerr, C., Pungliya, M.S.,
Alders,M.,Wilde, A.A., andAckerman,M.J. (2009). Genetic testing
for long-QT syndrome distinguishing pathogenic mutations from
benign variants. Circulation 120, 1752–1760.
Koumi, S., Backer, C.L., and Arentzen, C.E. (1995). Characteriza-
tion of inwardly rectifying K+ channel in human cardiacmyocytes.
Alterations in channel behavior inmyocytes isolated frompatients
with idiopathic dilated cardiomyopathy. Circulation 92, 164–174.
Li, H.L., Gee, P., Ishida, K., and Hotta, A. (2016). Efficient genomic
correctionmethods in human iPS cells using CRISPR-Cas9 system.
Methods 101, 27–35.
Lian, X., Zhang, J., Azarin, S.M., Zhu, K., Hazeltine, L.B., Bao, X.,
Hsiao, C., Kamp, T.J., and Palecek, S.P. (2013). Directed cardiomyo-
cyte differentiation from human pluripotent stem cells by modu-
lating Wnt/b-catenin signaling under fully defined conditions.
Nat. Protoc. 8, 162–175.
Ma, J., Guo, L., Fiene, S.J., Anson, B.D., Thomson, J.A., Kamp, T.J.,
Kolaja, K.L., Swanson, B.J., and January, C.T. (2011). High purity
human-induced pluripotent stem cell-derived cardiomyocytes:
electrophysiological properties of action potentials and ionic cur-
rents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006–E2017.
Moss, A.J., Zareba, W., Hall, W.J., and Schwartz, P.J. (2000). Effec-
tiveness and limitations of b-blocker therapy in congenital long-
QT syndrome. Circulation 101, 616–623.
Moss, A.J. (2003). Long QT syndrome. JAMA 289, 2041–2044.
Napolitano, C., Priori, S.G., Schwartz, P.J., Bloise, R., Ronchetti, E.,
Nastoli, J., Bottelli, G., Cerrone, M., and Leonardi, S. (2005). Ge-
netic testing in the long QT syndrome: development and valida-
tion of an efficient approach to genotyping in clinical practice.
JAMA 294, 2975–2980.
Priori, S.G., Napolitano, C., Schwartz, P.J., Grillo, M., Bloise, R.,
Ronchetti, E., Moncalvo, C., Tulipani, C., Veia, A., Bottelli, G.,
et al. (2004). Association of long QT syndrome loci and cardiac
events among patients treated with beta-blockers. JAMA 292,
1341–1344.
Priori, S.G., Wilde, A.A., Horie, M., Cho, Y., Behr, E.R., Berul, C.,
Blom, N., Brugada, J., Chiang, C.E., Huikuri, H., et al. (2013).
HRS/EHRA/APHRS expert consensus statement on the diagnosis
and management of patients with inherited primary arrhythmia
syndromes: document endorsed by HRS, EHRA, and APHRS in
May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.
Heart Rhythm 10, 1932–1963.Stem Cell Reports j Vol. 13 j 394–404 j August 13, 2019 403
Schwartz, P.J., Priori, S.G., Spazzolini, C., andMoss, A.J. (2001). Ge-
notype-phenotype correlation in the long-QT syndrome. Circula-
tion 103, 89–95.
Schwartz, P.J., Ackerman, M.J., George, A.L., and Wilde, A.A.M.
(2013). Impact of genetics on the clinical management of channe-
lopathies. J. Am. Coll. Cardiol. 62, 169–180.
Spencer, C.I., Baba, S., Nakamura, K., Hua, E.A., Sears, M.A., Fu,
C.C., Zhang, J., Balijepalli, S., Tomoda, K., Hayashi, Y., et al.
(2014). Calcium transients closely reflect prolonged action poten-
tials in iPSC models of inherited cardiac arrhythmia. Stem Cell Re-
ports 3, 269–281.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., To-
moda, K., and Yamanaka, S. (2007). Induction of pluripotent stem
cells from adult human fibroblasts by defined factors. Cell 107,
861–872.
Tohyama, S., Hattori, F., Sano, M., Hishiki, T., Nagahata, Y., Mat-
suura, T., Hashimoto, H., Suzuki, T., Yamashita, H., Satoh, Y.,404 Stem Cell Reports j Vol. 13 j 394–404 j August 13, 2019et al. (2013). Distinct metabolic flow enables large-scale purifica-
tion of mouse and human pluripotent stem cell-derived cardio-
myocytes. Cell Stem Cell 12, 127–137.
Van Putten, R.M.E.M., Mengarelli, I., Guan, K., Zegers, J.G., van
Ginneken, A.C., Verkerk, A.O., andWilders, R. (2015). Ion channe-
lopathies in human induced pluripotent stem cell derived
cardiomyocytes: a dynamic clamp study with virtual IK1. Front.
Physiol. 6, 7.
Wehrens, X.H., Vos, M.A., Doevendans, P.A., and Wellens, H.J.J.
(2002). Novel insights in the congenital long QT syndrome. Ann.
Intern. Med. 137, 981–992.
Wuriyanghai, Y., Makiyama, T., Sasaki, K., Kamakura, T., Yama-
moto, Y., Hayano, M., Harita, T., Nishiuchi, S., Chen, J., Kohjitani,
H., et al. (2018). Complex aberrant splicing in the induced plurip-
otent stem cell-derived cardiomyocytes from a patient with long
QTsyndrome carrying KCNQ1-A344Asplmutation. Heart Rhythm
15, 1566–1574.
